Notice of Executive Officer Personnel Changes and Organizational Restructuring

Summary of Personnel and Organizational Revisions

Fuso Pharmaceutical Industries,Ltd. will implement executive officer personnel changes and organizational restructuring, approved by the Board of Directors, effective January 1, 2027. Planned resignation: Satoshi Tanaka (current Executive Officer, Head of Reliability Assurance Division). New appointments: Kazuhisa Iwamoto (Executive Officer, Head of Reliability Assurance Division) and Satoshi Maruyama (current position: Head of Safety Management Headquarters, Reliability Assurance Division; the exact official reading of the given name is uncertain from the document). Organizationally, within the Reliability Assurance Division a Safety Management Headquarters will be created, establishing a Safety Management Section and a Global PV Audit Section.

Impact and Outlook

Strengthening the Safety Management Headquarters is intended to enhance the quality and reliability assurance framework, and the establishment of the Global PV Audit Section indicates an enhancement of audit functions for global operations. The resignation and appointments are expected to promote comprehensive quality assurance and regulatory compliance, potentially contributing to stronger governance in business operations.